REGENERON PHARMACEUTICALS, INC.·4

Feb 8, 4:02 PM ET

STAHL NEIL 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 8, 2024

Insider Transaction Report

Form 4
Period: 2024-02-07
STAHL NEIL
SVP Res and Dev Sciences
Transactions
  • Sale

    Common Stock

    2024-02-07$947.34/sh100$94,73459,956 total
  • Sale

    Common Stock

    2024-02-07$949.45/sh601$570,61957,461 total
  • Sale

    Common Stock

    2024-02-07$951.49/sh1,237$1,176,99353,097 total
  • Sale

    Common Stock

    2024-02-07$953.00/sh19$18,10752,019 total
  • Sale

    Common Stock

    2024-02-07$948.69/sh1,894$1,796,81958,062 total
  • Sale

    Common Stock

    2024-02-07$950.43/sh3,127$2,971,99554,334 total
  • Sale

    Common Stock

    2024-02-07$952.49/sh1,059$1,008,68752,038 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    5,834
  • Common Stock

    (indirect: By Trust)
    4,605
Footnotes (5)
  • [F1]Represents volume-weighted average price of sales of 1,894 shares of Company stock on February 7, 2024 at prices ranging from $948.19 to $948.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price.
  • [F2]Represents volume-weighted average price of sales of 601 shares of Company stock on February 7, 2024 at prices ranging from $949.22 to $949.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price.
  • [F3]Represents volume-weighted average price of sales of 3,127 shares of Company stock on February 7, 2024 at prices ranging from $950.00 to $950.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price.
  • [F4]Represents volume-weighted average price of sales of 1,237 shares of Company stock on February 7, 2024 at prices ranging from $951.00 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price.
  • [F5]Represents volume-weighted average price of sales of 1,059 shares of Company stock on February 7, 2024 at prices ranging from $952.03 to $952.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT